Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07527806) titled 'Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging' on April 7.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Peking University Cancer Hospital & Institute
Condition:
Breast Cancer
Intervention:
Drug: Trastuzumab (Herceptin)
Drug: Pertuzumab
Drug: Combination product: Trastuzumab + Pertuzumab
Drug: Docetaxel or Nab-paclitaxel
Drug: carboplatin
Drug: CDK4/6 inhibitor
Drug: Aromatase Inhibitor (AI)
Rec...